NCT02438904 Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
| NCT ID | NCT02438904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Blood And Marrow Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2015-05-06 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2015-05-06 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
Eligibility Criteria
Inclusion Criteria: 1\) Patients who have poor or no graft function post stem cell transplantation. Exclusion Criteria: N/A
Contact & Investigator
Elizabeth Shpall, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT02438904 clinical trial?
This trial is open to participants of all sexes, studying Blood And Marrow Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02438904 currently recruiting?
Yes, NCT02438904 is actively recruiting participants. Contact the research team at eshpall@mdanderson.org for enrollment information.
Where is the NCT02438904 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT02438904 clinical trial?
NCT02438904 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Elizabeth Shpall, MD at M.D. Anderson Cancer Center. The trial plans to enroll 200 participants.